Suppr超能文献

一名慢性乙型肝炎患者体内对拉米夫定、阿德福韦酯和恩替卡韦具有多重耐药性的乙肝病毒株的演变与抑制

Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.

作者信息

Liu Yan, Wang Chunmei, Zhong Yanwei, Chen Li, Li Xiaodong, Ji Dong, Wang Huifen, Xin Shaojie, Zoulim Fabien, Xu Dongping

机构信息

Viral Hepatitis Research Laboratory, Beijing Institute of Infectious Diseases, Beijing, China.

出版信息

Antivir Ther. 2010;15(8):1185-90. doi: 10.3851/IMP1679.

Abstract

Here, we report a case of multidrug resistance in a patient with chronic hepatitis B. The patient sequentially received lamivudine, adefovir dipivoxil and entecavir, and subsequently developed single-, double- and triple-drug-resistant HBV strains. We consider this case report important because it documents, for the first time, that triple-drug-resistant HBV strains identified in a clinical setting were suppressible by lamivudine add-on adefovir dipivoxil when tenofovir disoproxil fumarate was not available.

摘要

在此,我们报告一例慢性乙型肝炎患者的多重耐药病例。该患者先后接受了拉米夫定、阿德福韦酯和恩替卡韦治疗,随后出现了对单一药物、两种药物和三种药物耐药的乙肝病毒株。我们认为该病例报告很重要,因为它首次记录了在临床环境中鉴定出的三重耐药乙肝病毒株,在无法获得富马酸替诺福韦二吡呋酯时,可通过加用阿德福韦酯的拉米夫定进行抑制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验